Advances in the clinical management of uveal melanoma.
Journal
Nature reviews. Clinical oncology
ISSN: 1759-4782
Titre abrégé: Nat Rev Clin Oncol
Pays: England
ID NLM: 101500077
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
accepted:
16
11
2022
pubmed:
5
1
2023
medline:
27
1
2023
entrez:
4
1
2023
Statut:
ppublish
Résumé
Melanomas arising in the uveal tract of the eye are a rare form of the disease with a biology and clinical phenotype distinct from their more common cutaneous counterparts. Treatment of primary uveal melanoma with radiotherapy, enucleation or other modalities achieves local control in more than 90% of patients, although 40% or more ultimately develop distant metastases, most commonly in the liver. Until January 2022, no systemic therapy had received regulatory approval for patients with metastatic uveal melanoma, and these patients have historically had a dismal prognosis owing to the limited efficacy of the available treatments. A series of seminal studies over the past two decades have identified highly prevalent early, tumour-initiating oncogenic genomic aberrations, later recurring prognostic alterations and immunological features that characterize uveal melanoma. These advances have driven the development of a number of novel emerging treatments, including tebentafusp, the first systemic therapy to achieve regulatory approval for this disease. In this Review, our multidisciplinary and international group of authors summarize the biology of uveal melanoma, management of primary disease and surveillance strategies to detect recurrent disease, and then focus on the current standard and emerging regional and systemic treatment approaches for metastatic uveal melanoma.
Identifiants
pubmed: 36600005
doi: 10.1038/s41571-022-00714-1
pii: 10.1038/s41571-022-00714-1
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
99-115Informations de copyright
© 2023. Springer Nature Limited.
Références
Shields, C. L. et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch. Ophthalmol. 127, 989–998 (2009).
doi: 10.1001/archophthalmol.2009.208
Hu, D. N., Yu, G. P., McCormick, S. A., Schneider, S. & Finger, P. T. Population-based incidence of uveal melanoma in various races and ethnic groups. Am. J. Ophthalmol. 140, 612–617 (2005).
doi: 10.1016/j.ajo.2005.05.034
Virgili, G. et al. Incidence of uveal melanoma in Europe. Ophthalmology 114, 2309–2315 (2007).
doi: 10.1016/j.ophtha.2007.01.032
Vajdic, C. M. et al. Incidence of ocular melanoma in Australia from 1990 to 1998. Int. J. Cancer 105, 117–122 (2003).
doi: 10.1002/ijc.11057
Aronow, M. E., Topham, A. K. & Singh, A. D. Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER 1973-2013). Ocul. Oncol. Pathol. 4, 145–151 (2018).
doi: 10.1159/000480640
Robertson, A. G. et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 32, 204–220.e15 (2017).
doi: 10.1016/j.ccell.2017.07.003
Royer-Bertrand, B. et al. Comprehensive genetic landscape of uveal melanoma by whole-genome sequencing. Am. J. Hum. Genet. 99, 1190–1198 (2016).
doi: 10.1016/j.ajhg.2016.09.008
Johansson, P. A. et al. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. Nat. Commun. 11, 2408 (2020).
doi: 10.1038/s41467-020-16276-8
Nayman, T., Bostan, C., Logan, P. & Burnier, M. N. Jr Uveal melanoma risk factors: a systematic review of meta-analyses. Curr. Eye Res. 42, 1085–1093 (2017).
doi: 10.1080/02713683.2017.1297997
Robinson, S. et al. Protection against UVR involves MC1R-mediated non-pigmentary and pigmentary mechanisms in vivo. J. Invest. Dermatol. 130, 1904–1913 (2010).
doi: 10.1038/jid.2010.48
Böhm, M. et al. α-Melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage. J. Biol. Chem. 280, 5795–5802 (2005).
doi: 10.1074/jbc.M406334200
Hauser, J. E. et al. Melanin content and MC1R function independently affect UVR-induced DNA damage in cultured human melanocytes. Pigment. Cell Res. 19, 303–314 (2006).
doi: 10.1111/j.1600-0749.2006.00315.x
Shields, C. L. et al. Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: analysis of 7872 consecutive eyes. JAMA Ophthalmol. 131, 993–1003 (2013).
doi: 10.1001/jamaophthalmol.2013.129
Shields, J. A., Demirci, H., Mashayekhi, A. & Shields, C. L. Melanocytoma of optic disc in 115 cases: the 2004 Samuel Johnson Memorial Lecture, part 1. Ophthalmology 111, 1739–1746 (2004).
Singh, A. D. et al. Lifetime prevalence of uveal melanoma in white patients with oculo(dermal) melanocytosis. Ophthalmology 105, 195–198 (1998).
doi: 10.1016/S0161-6420(98)92205-9
Abdel-Rahman, M. H. et al. Whole exome sequencing identifies candidate genes associated with hereditary predisposition to uveal melanoma. Ophthalmology 127, 668–678 (2020).
doi: 10.1016/j.ophtha.2019.11.009
Harbour, J. W. The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment. Cell Melanoma Res. 25, 171–181 (2012).
doi: 10.1111/j.1755-148X.2012.00979.x
Singh, N., Singh, R., Bowen, R. C., Abdel-Rahman, M. H. & Singh, A. D. Uveal melanoma in BAP1 tumor predisposition syndrome: estimation of risk. Am. J. Ophthalmol. 224, 172–177 (2021).
doi: 10.1016/j.ajo.2020.12.005
Honavar, S. G., Singh, A. D., Shields, C. L., Shields, J. A. & Eagle, R. C. Jr. Iris melanoma in a patient with neurofibromatosis. Surv. Ophthalmol. 45, 231–236 (2000).
doi: 10.1016/S0039-6257(00)00154-5
Rodrigues, M. et al. Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors. Nat. Commun. 9, 1866 (2018).
doi: 10.1038/s41467-018-04322-5
Derrien, A. C. et al. Germline MBD4 mutations and predisposition to uveal melanoma. J. Natl Cancer Inst. 113, 80–87 (2021).
doi: 10.1093/jnci/djaa047
Garg, G. et al. Patients presenting with metastases: stage IV uveal melanoma, an international study. Br. J. Ophthalmol. 106, 510–517 (2022).
doi: 10.1136/bjophthalmol-2020-317949
Eskelin, S. & Kivela, T. Mode of presentation and time to treatment of uveal melanoma in Finland. Br. J. Ophthalmol. 86, 333–338 (2002).
doi: 10.1136/bjo.86.3.333
Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch. Ophthalmol. 119, 670–676 (2001).
doi: 10.1001/archopht.119.5.670
Khoja, L. et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann. Oncol. 30, 1370–1380 (2019).
doi: 10.1093/annonc/mdz176
Rantala, E. S., Hernberg, M. & Kivela, T. T. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 29, 561–568 (2019).
doi: 10.1097/CMR.0000000000000575
Carvajal, R. D. et al. Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma. J. Clin. Oncol. 40, 1939–1948 (2022).
doi: 10.1200/JCO.21.01805
Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196–1206 (2021).
doi: 10.1056/NEJMoa2103485
McLean, M. J., Foster, W. D. & Zimmerman, L. E. Prognostic factors in small malignant melanomas of choroid and ciliary body. Arch. Ophthalmol. 95, 48–58 (1977).
doi: 10.1001/archopht.1977.04450010050004
Bronkhorst, I. H. et al. Detection of M2-macrophages in uveal melanoma and relation with survival. Invest. Ophthalmol. Vis. Sci. 52, 643–650 (2011).
doi: 10.1167/iovs.10-5979
Folberg, R. et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 100, 1389–1398 (1993).
doi: 10.1016/S0161-6420(93)31470-3
Jager, M. J. et al. Uveal melanoma. Nat. Rev. Dis. Prim. 6, 24 (2020).
doi: 10.1038/s41572-020-0158-0
Van Raamsdonk, C. D. et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457, 599–602 (2009).
doi: 10.1038/nature07586
Van Raamsdonk, C. D. et al. Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 363, 2191–2199 (2010).
doi: 10.1056/NEJMoa1000584
Moore, A. R. et al. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat. Genet. 48, 675–680 (2016).
doi: 10.1038/ng.3549
Johansson, P. et al. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget 7, 4624–4631 (2016).
doi: 10.18632/oncotarget.6614
Chen, X. et al. RasGRP3 mediates MAPK pathway activation in GNAQ mutant uveal melanoma. Cancer Cell 31, 685–696.e6 (2017).
doi: 10.1016/j.ccell.2017.04.002
Ambrosini, G., Musi, E., Ho, A. L., de Stanchina, E. & Schwartz, G. K. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. Mol. Cancer Ther. 12, 768–776 (2013).
doi: 10.1158/1535-7163.MCT-12-1020
Feng, X. et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell 25, 831–845 (2014).
doi: 10.1016/j.ccr.2014.04.016
Harbour, J. W. et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410–1413 (2010).
doi: 10.1126/science.1194472
Carbone, M. et al. BAP1 and cancer. Nat. Rev. Cancer 13, 153–159 (2013).
doi: 10.1038/nrc3459
Maat, W. et al. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 49, 505–510 (2008).
doi: 10.1167/iovs.07-0786
de Lange, M. J. et al. Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma. Oncotarget 6, 37824–37835 (2015).
doi: 10.18632/oncotarget.5637
Gezgin, G. et al. Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment. Cancer Immunol. Immunother. 66, 903–912 (2017).
doi: 10.1007/s00262-017-1991-1
Brouwer, N. J. et al. Ischemia is related to tumour genetics in uveal melanoma. Cancers https://doi.org/10.3390/cancers11071004 (2019).
doi: 10.3390/cancers11071004
Bronkhorst, I. H. et al. Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 53, 5370–5378 (2012).
doi: 10.1167/iovs.11-9280
Makitie, T., Summanen, P., Tarkkanen, A. & Kivela, T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 42, 1414–1421 (2001).
Krishna, Y., McCarthy, C., Kalirai, H. & Coupland, S. E. Inflammatory cell infiltrates in advanced metastatic uveal melanoma. Hum. Pathol. 66, 159–166 (2017).
doi: 10.1016/j.humpath.2017.06.005
Tosi, A. et al. The immune cell landscape of metastatic uveal melanoma correlates with overall survival. J. Exp. Clin. Cancer Res. 40, 154 (2021).
doi: 10.1186/s13046-021-01947-1
Qin, Y. et al. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: a pilot study. Oncoimmunology 6, e1321187 (2017).
doi: 10.1080/2162402X.2017.1321187
Rothermel, L. D. et al. Identification of an immunogenic subset of metastatic uveal melanoma. Clin. Cancer Res. 22, 2237–2249 (2016).
doi: 10.1158/1078-0432.CCR-15-2294
Yu, J. et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat. Med. 27, 152–164 (2021).
doi: 10.1038/s41591-020-1131-x
Karlsson, J. et al. Molecular profiling of driver events in metastatic uveal melanoma. Nat. Commun. 11, 1894 (2020).
doi: 10.1038/s41467-020-15606-0
Durante, M. A. et al. Single-cell analysis reveals new evolutionary complexity in uveal melanoma. Nat. Commun. 11, 496 (2020).
doi: 10.1038/s41467-019-14256-1
Souri, Z. et al. LAG3 and its ligands show increased expression in high-risk uveal melanoma. Cancers https://doi.org/10.3390/cancers13174445 (2021).
doi: 10.3390/cancers13174445
Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report no. 28. Arch. Ophthalmol. 124, 1684–1693 (2006).
doi: 10.1001/archopht.124.12.1684
Jampol, L. M. et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology 109, 2197–2206 (2002).
doi: 10.1016/S0161-6420(02)01277-0
Ophthalmic Oncology Task Force. Local recurrence significantly increases the risk of metastatic uveal melanoma. Ophthalmology 123, 86–91 (2016).
doi: 10.1016/j.ophtha.2015.09.014
Caujolle, J. P. et al. Local recurrence after uveal melanoma proton beam therapy: recurrence types and prognostic consequences. Int. J. Radiat. Oncol. Biol. Phys. 85, 1218–1224 (2013).
doi: 10.1016/j.ijrobp.2012.10.005
Gragoudas, E. S., Lane, A. M., Munzenrider, J., Egan, K. M. & Li, W. Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. Trans. Am. Ophthalmol. Soc. 100, 43–48 (2002). discussion 48-49.
Augsburger, J. J., Correa, Z. M., Freire, J. & Brady, L. W. Long-term survival in choroidal and ciliary body melanoma after enucleation versus plaque radiation therapy. Ophthalmology 105, 1670–1678 (1998).
doi: 10.1016/S0161-6420(98)99037-6
Mosci, C. et al. Comparison of clinical outcomes for patients with large choroidal melanoma after primary treatment with enucleation or proton beam radiotherapy. Ophthalmologica 227, 190–196 (2012).
doi: 10.1159/000334401
Dinca, E. B. et al. Survival and complications following Gamma Knife radiosurgery or enucleation for ocular melanoma: a 20-year experience. Acta Neurochir. 154, 605–610 (2012).
doi: 10.1007/s00701-011-1252-6
Chang, M. Y. & McCannel, T. A. Local treatment failure after globe-conserving therapy for choroidal melanoma. Br. J. Ophthalmol. 97, 804–811 (2013).
doi: 10.1136/bjophthalmol-2012-302490
Shields, C. L. et al. Iris melanoma outcomes based on the American Joint Committee on cancer classification (eighth edition) in 432 patients. Ophthalmology 125, 913–923 (2018).
doi: 10.1016/j.ophtha.2017.11.040
Force, A. O. O. T. International validation of the American Joint Committee on cancer’s 7th edition classification of uveal melanoma. JAMA Ophthalmol. 133, 376–383 (2015).
doi: 10.1001/jamaophthalmol.2014.5395
Kivelä, T. et al. in AJCC Cancer Staging Manual 8th edn (eds Amin, M. B. et al.) 805–817 (Springer, 2016).
Dogrusoz, M. et al. The prognostic value of AJCC staging in uveal melanoma is enhanced by adding chromosome 3 and 8q status. Invest. Ophthalmol. Vis. Sci. 58, 833–842 (2017).
doi: 10.1167/iovs.16-20212
Stacey, A. W., Dedania, V. S., Materin, M. & Demirci, H. Improved prognostic precision in uveal melanoma through a combined score of clinical stage and molecular prognostication. Ocul. Oncol. Pathol. 8, 35–41 (2022).
doi: 10.1159/000520218
National Comprehensive Cancer Network. Melanoma: Uveal (version 2.2022) NCCN https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1488 (2022).
Nathan, P. et al. Uveal melanoma UK national guidelines. Eur. J. Cancer 51, 2404–2412 (2015).
doi: 10.1016/j.ejca.2015.07.013
Singh, A. D. et al. Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications. Br. J. Ophthalmol. 100, 456–462 (2016).
doi: 10.1136/bjophthalmol-2015-306921
Sellam, A. et al. Fine needle aspiration biopsy in uveal melanoma: technique, complications, and outcomes. Am. J. Ophthalmol. 162, 28–34.e1 (2016).
doi: 10.1016/j.ajo.2015.11.005
Prescher, G. et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347, 1222–1225 (1996).
doi: 10.1016/S0140-6736(96)90736-9
Damato, B. et al. Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology 114, 1925–1931 (2007).
doi: 10.1016/j.ophtha.2007.06.012
Scholes, A. G. et al. Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest. Ophthalmol. Vis. Sci. 44, 1008–1011 (2003).
doi: 10.1167/iovs.02-0159
Sisley, K. et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 19, 22–28 (1997).
doi: 10.1002/(SICI)1098-2264(199705)19:1<22::AID-GCC4>3.0.CO;2-2
Ewens, K. G. et al. Genomic profile of 320 uveal melanoma cases: chromosome 8p-loss and metastatic outcome. Invest. Ophthalmol. Vis. Sci. 54, 5721–5729 (2013).
doi: 10.1167/iovs.13-12195
Damato, B., Dopierala, J. A. & Coupland, S. E. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin. Cancer Res. 16, 6083–6092 (2010).
doi: 10.1158/1078-0432.CCR-10-2076
Shields, C. L. et al. Ten-year outcomes of uveal melanoma based on The Cancer Genome Atlas (TCGA) classification in 1001 cases. Indian J. Ophthalmol. 69, 1839–1845 (2021).
doi: 10.4103/ijo.IJO_313_21
Gelmi, M. C. et al. Adding The Cancer Genome Atlas chromosome classes to American Joint Committee on cancer system offers more precise prognostication in uveal melanoma. Ophthalmology 129, 431–437 (2022).
doi: 10.1016/j.ophtha.2021.11.018
Shao, Y. F., Echegaray, J. J., Singh, N. & Singh, A. D. Variability of bad prognosis in uveal melanoma. Ophthalmol. Retin. 3, 186–193 (2019).
doi: 10.1016/j.oret.2018.09.007
Cunha Rola, A. et al. Multicenter external validation of the Liverpool uveal melanoma prognosticator online: an OOG collaborative study. Cancers 12, 477 (2020).
doi: 10.3390/cancers12020477
Impactgenetics. Uveal melanoma: prognostic genetic test. Impactgenetics https://impactgenetics.com/wp-content/uploads/2019/03/UM-Test-Description-11Mar2019.pdf (2019).
Farquhar, N. et al. Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma. J. Pathol. Clin. Res. 4, 26–38 (2018).
doi: 10.1002/cjp2.86
Yavuzyigitoglu, S. et al. Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases. Ophthalmology 123, 1118–1128 (2016).
doi: 10.1016/j.ophtha.2016.01.023
Castle Biosciences. DecisionDx-UMSeq overview. Castle Biosciences https://castletestinfo.com/products/decisiondx-um-overview/decisiondx-umseq/ (2022).
Afshar, A. R. et al. Next-generation sequencing of uveal melanoma for detection of genetic alterations predicting metastasis. Transl. Vis. Sci. Technol. 8, 18 (2019).
doi: 10.1167/tvst.8.2.18
Demirci, H. et al. Do largest basal tumor diameter and the American Joint Committee on Cancer’s cancer staging influence prognostication by gene expression profiling in choroidal melanoma. Am. J. Ophthalmol. 195, 83–92 (2018).
doi: 10.1016/j.ajo.2018.07.033
Onken, M. D., Worley, L. A., Ehlers, J. P. & Harbour, J. W. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 64, 7205–7209 (2004).
doi: 10.1158/0008-5472.CAN-04-1750
Onken, M. D. et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 119, 1596–1603 (2012).
doi: 10.1016/j.ophtha.2012.02.017
Aaberg, T. M. et al. Gene expression profiling in uveal melanoma: five-year prospective outcomes and meta-analysis. Ocul. Oncol. Pathol. 6, 360–367 (2020).
doi: 10.1159/000508382
Schefler, A. C. et al. Design, methods, and rationale for the Collaborative Ocular Oncology Group 2 (COOG2) study [abstract]. Investig. Ophthalmol. Vis. Sci. 62, 2870 (2021).
Binkley, E. M. et al. Gene expression profiling prognostication of posterior uveal melanoma: does size matter? Ophthalmol. Retin. 4, 620–629 (2020).
doi: 10.1016/j.oret.2019.12.020
Wong, A. J. et al. Three-year outcomes of uveal melanoma treated with intra-operative ultrasound-guided iodine-125 brachytherapy using custom-built eye plaques. J. Contemp. Brachytherapy 14, 130–139 (2022).
doi: 10.5114/jcb.2022.115379
Decatur, C. L. et al. Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 134, 728–733 (2016).
doi: 10.1001/jamaophthalmol.2016.0903
Field, M. G. et al. PRAME as an independent biomarker for metastasis in uveal melanoma. Clin. Cancer Res. 22, 1234–1242 (2016).
doi: 10.1158/1078-0432.CCR-15-2071
Ballhausen, A. et al. Metastatic risk factors associated with class 1A uveal melanoma patients. Cancers https://doi.org/10.3390/cancers13133292 (2021).
doi: 10.3390/cancers13133292
Field, M. G. et al. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in class 1 and class 2 uveal melanomas. Oncotarget 7, 59209–59219 (2016).
doi: 10.18632/oncotarget.10962
Castle Biosciences. Uveal melanoma: DecisionDx-PRAME. Castle Biosciences https://castlebiosciences.com/products/decisiondx-prame-testing/ (2022).
Kujala, E., Makitie, T. & Kivela, T. Very long-term prognosis of patients with malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 44, 4651–4659 (2003).
doi: 10.1167/iovs.03-0538
Diener-West, M. et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group report no. 26. Arch. Ophthalmol. 123, 1639–1643 (2005).
doi: 10.1001/archopht.123.12.1639
Rietschel, P. et al. Variates of survival in metastatic uveal melanoma. J. Clin. Oncol. 23, 8076–8080 (2005).
doi: 10.1200/JCO.2005.02.6534
Wei, A. Z. et al. Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases. Front. Oncol. https://doi.org/10.3389/fonc.2022.961517 (2022).
doi: 10.3389/fonc.2022.961517
Servois, V. et al. Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET). Eur. J. Surg. Oncol. 36, 189–194 (2010).
doi: 10.1016/j.ejso.2009.08.010
Francis, J. H. et al. Hepatic abnormalities identified by staging MRI and accuracy of MRI of patients with uveal melanoma. Br. J. Ophthalmol. 103, 1266–1271 (2019).
doi: 10.1136/bjophthalmol-2018-312612
Hicks, C., Foss, A. J. & Hungerford, J. L. Predictive power of screening tests for metastasis in uveal melanoma. Eye 12, 945–948 (1998).
doi: 10.1038/eye.1998.245
Rantala, E. S., Peltola, E., Helminen, H., Hernberg, M. & Kivela, T. T. Hepatic ultrasonography compared with computed tomography and magnetic resonance imaging at diagnosis of metastatic uveal melanoma. Am. J. Ophthalmol. 216, 156–164 (2020).
doi: 10.1016/j.ajo.2020.03.049
Orcurto, V. et al.
doi: 10.1097/CMR.0b013e32834d3dcb
Marshall, E. et al. MRI in the detection of hepatic metastases from high-risk uveal melanoma: a prospective study in 188 patients. Br. J. Ophthalmol. 97, 159–163 (2013).
doi: 10.1136/bjophthalmol-2012-302323
Diener-West, M. et al. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group report 23. J. Clin. Oncol. 22, 2438–2444 (2004).
doi: 10.1200/JCO.2004.08.194
Gombos, D. S., Van Quill, K. R., Uusitalo, M. & O’Brien, J. M. Geographic disparities in diagnostic screening for metastatic uveal melanoma. Ophthalmology 111, 2254–2258 (2004).
doi: 10.1016/j.ophtha.2004.06.022
Daniels, A. B. et al. Impact of different initial systemic staging imaging strategies on metastasis detection in uveal melanoma patients: the Melanoma of the Uvea Staging Imaging Consortium (MUSIC) study [abstract]. Invest. Ophthalmol. Vis. Sci. 61, 4027 (2020).
McLean, I. W. et al. A randomized study of methanol-extraction residue of bacille Calmette-Guerin as postsurgical adjuvant therapy of uveal melanoma. Am. J. Ophthalmol. 110, 522–526 (1990).
doi: 10.1016/S0002-9394(14)77876-6
Desjardins, L. et al. Etude randomisée de chimiothérapie adjuvante par le Déticène dans le mélanome choroïdien [French]. Ophtalmologie 12, 168–173 (1998).
Piperno-Neumann, S. et al. A randomized multicenter phase 3 trial of adjuvant fotemustine versus surveillance in high risk uveal melanoma (UM) patients (FOTEADJ) [abstract]. J. Clin. Oncol. 35 (Suppl. 15), 9502 (2017).
doi: 10.1200/JCO.2017.35.15_suppl.9502
Seedor, R. S. et al. Randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma: the final analysis of cohort 1 [abstract]. J. Clin. Oncol. 40 (Suppl. 16), 9586 (2022).
doi: 10.1200/JCO.2022.40.16_suppl.9586
Lane, A. M. et al. Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. Ophthalmology 116, 2206–2212 (2009).
doi: 10.1016/j.ophtha.2009.04.044
Voelter, V. et al. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients. Melanoma Res. 18, 220–224 (2008).
doi: 10.1097/CMR.0b013e32830317de
Fountain, E. et al. Adjuvant ipilimumab in high-risk uveal melanoma. Cancers https://doi.org/10.3390/cancers11020152 (2019).
doi: 10.3390/cancers11020152
Binkley, E. et al. A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes. Br. J. Ophthalmol. 104, 524–528 (2020).
doi: 10.1136/bjophthalmol-2019-314461
Khan, S. et al. Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy. Front. Oncol. 12, 976837 (2022).
doi: 10.3389/fonc.2022.976837
Abdel-Rahman, M. H., Boru, G., Massengill, J., Salem, M. M. & Davidorf, F. H. MET oncogene inhibition as a potential target of therapy for uveal melanomas. Investig. Ophthalmol. Vis. Sci. 51, 3333–3339 (2010).
doi: 10.1167/iovs.09-4801
Surriga, O. et al. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model. Mol. Cancer Ther. 12, 2817–2826 (2013).
doi: 10.1158/1535-7163.MCT-13-0499
Valsecchi, M. E. et al. Adjuvant sunitinib in high-risk patients with uveal melanoma: comparison with institutional controls. Ophthalmology 125, 210–217 (2018).
doi: 10.1016/j.ophtha.2017.08.017
Landreville, S. et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin. Cancer Res. 18, 408–416 (2012).
doi: 10.1158/1078-0432.CCR-11-0946
Souri, Z. et al. HDAC inhibition increases HLA class I expression in uveal melanoma. Cancers https://doi.org/10.3390/cancers12123690 (2020).
doi: 10.3390/cancers12123690
Kuznetsoff, J. N. et al. Dual screen for efficacy and toxicity identifies HDAC inhibitor with distinctive activity spectrum for BAP1-mutant uveal melanoma. Mol. Cancer Res. 19, 215–222 (2021).
doi: 10.1158/1541-7786.MCR-20-0434
Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24–34 (2022).
doi: 10.1056/NEJMoa2109970
Furney, S. J. et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 3, 1122–1129 (2013).
doi: 10.1158/2159-8290.CD-13-0330
Saint-Ghislain, M. et al. MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients. Eur. J. Cancer 173, 105–112 (2022).
doi: 10.1016/j.ejca.2022.06.033
Mariani, P. et al. Surgical management of liver metastases from uveal melanoma: 16 years’ experience at the Institut Curie. Eur. J. Surg. Oncol. 35, 1192–1197 (2009).
doi: 10.1016/j.ejso.2009.02.016
Sterbis, E. et al. Safety and efficacy of microwave ablation for uveal melanoma metastatic to the liver [abstract 184]. J. Vasc. Interv. Radiol. 30 (Suppl. 3), S84 (2019).
doi: 10.1016/j.jvir.2018.12.238
Mariani, P. et al. Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma. Eur. J. Surg. Oncol. 42, 706–712 (2016).
doi: 10.1016/j.ejso.2016.02.019
Rivoire, M. et al. Treatment of liver metastases from uveal melanoma. Ann. Surg. Oncol. 12, 422–428 (2005).
doi: 10.1245/ASO.2005.06.032
Rowcroft, A., Loveday, B. P. T., Thomson, B. N. J., Banting, S. & Knowles, B. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB 22, 497–505 (2020).
doi: 10.1016/j.hpb.2019.11.002
Leyvraz, S. et al. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. Ann. Oncol. 25, 742–746 (2014).
doi: 10.1093/annonc/mdt585
Gonsalves, C. F. et al. A prospective phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis. Radiology 293, 223–231 (2019).
doi: 10.1148/radiol.2019190199
Peuker, C.-A. A. et al. First interim analysis of the SirTac trial: a randomized phase II study of SIRT and DSM-TACE in patients with liver metastases from uveal melanoma [abstract]. J. Clin. Oncol. 40 (Suppl. 16), 9511 (2022).
doi: 10.1200/JCO.2022.40.16_suppl.9511
Valsecchi, M. E. et al. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases. J. Vasc. Interv. Radiol. 26, 523–532.e2 (2015).
doi: 10.1016/j.jvir.2014.11.037
Yamamoto, A. et al. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology 252, 290–298 (2009).
doi: 10.1148/radiol.2521081252
Gonsalves, C. F., Eschelman, D. J., Thornburg, B., Frangos, A. & Sato, T. Uveal melanoma metastatic to the liver: chemoembolization with 1,3-bis-(2-chloroethyl)-1-nitrosourea. AJR Am. J. Roentgenol. 205, 429–433 (2015).
doi: 10.2214/AJR.14.14001
Tan, A., Eschelman, D., Gonsalves, C., Frangos, A. & Sato, T. Treatment of bulky uveal melanoma (UM) hepatic metastases with doxorubicin eluting beads (DEBDOX) followed by 1,3-bis(2-chloroethyl)-1-nitrosurea (BCNU) TACE: an initial experience [abstract 84]. J. Vasc. Interv. Radiol. 25 (Suppl. 3), S45 (2014).
doi: 10.1016/j.jvir.2013.12.107
Bagge, R. O. et al. Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases, first results from a phase III randomized controlled multicenter trial (the SCANDIUM trial) [abstract]. J. Clin. Oncol. 40 (Suppl. 17), LBA9509 (2022).
doi: 10.1200/JCO.2022.40.17_suppl.LBA9509
Zager, J. S. et al. FOCUS phase 3 trial results: percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A) [abstract]. J. Clin. Oncol. 40 (Suppl. 16), 9510 (2022).
doi: 10.1200/JCO.2022.40.16_suppl.9510
Olofsson, R. et al. Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit. Ann. Surg. Oncol. 21, 466–472 (2014).
doi: 10.1245/s10434-013-3304-z
Hughes, M. S. et al. Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases. Ann. Surg. Oncol. 23, 1309–1319 (2016).
doi: 10.1245/s10434-015-4968-3
Schmittel, A. et al. A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann. Oncol. 17, 1826–1829 (2006).
doi: 10.1093/annonc/mdl309
Sacco, J. J. et al. Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma [abstract]. J. Clin. Oncol. 31 (Suppl. 15), 9031 (2013).
doi: 10.1200/jco.2013.31.15_suppl.9031
Carvajal, R. D. et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA 311, 2397–2405 (2014).
doi: 10.1001/jama.2014.6096
Shoushtari, A. N. et al. A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced uveal melanoma [abstract]. J. Clin. Oncol. 34(Suppl. 15), 9511 (2016).
doi: 10.1200/JCO.2016.34.15_suppl.9511
Carvajal, R. D. et al. Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT). J. Clin. Oncol. 36, 1232–1239 (2018).
doi: 10.1200/JCO.2017.74.1090
Nathan, P. et al. SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM) [abstract LBA73]. Ann. Oncol. 30 (Suppl. 5), v908–v910 (2019).
doi: 10.1093/annonc/mdz394.070
Luke, J. J. et al. Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201). Clin. Cancer Res. 26, 804–811 (2020).
doi: 10.1158/1078-0432.CCR-19-1223
Bedikian, A. Y., Papadopoulos, N., Plager, C., Eton, O. & Ring, S. Phase II evaluation of temozolomide in metastatic choroidal melanoma. Melanoma Res. 13, 303–306 (2003).
doi: 10.1097/00008390-200306000-00013
Schmidt-Hieber, M., Schmittel, A., Thiel, E. & Keilholz, U. A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma. Melanoma Res. 14, 439–442 (2004).
doi: 10.1097/00008390-200412000-00001
O’Neill, P. A., Butt, M., Eswar, C. V., Gillis, P. & Marshall, E. A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma. Melanoma Res. 16, 245–248 (2006).
doi: 10.1097/01.cmr.0000205017.38859.07
Bhatia, S. et al. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PLoS ONE 7, e48787 (2012).
doi: 10.1371/journal.pone.0048787
Guenterberg, K. D. et al. A pilot study of bevacizumab and interferon-α2b in ocular melanoma. Am. J. Clin. Oncol. 34, 87–91 (2011).
doi: 10.1097/COC.0b013e3181d2ed67
Tarhini, A. A. et al. Aflibercept (VEGF Trap) in inoperable stage III or stage IV melanoma of cutaneous or uveal origin. Clin. Cancer Res. 17, 6574–6581 (2011).
doi: 10.1158/1078-0432.CCR-11-1463
Piperno-Neumann, S. et al. Phase II trial of bevacizumab in combination with temozolomide as first-line treatment in patients with metastatic uveal melanoma. Oncologist 21, 281–282 (2016).
doi: 10.1634/theoncologist.2015-0501
Penel, N. et al. O-Mel-Inib: a Cancero-pole Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma. Invest. N. Drugs 26, 561–565 (2008).
doi: 10.1007/s10637-008-9143-2
Hofmann, U. B., Kauczok-Vetter, C. S., Houben, R. & Becker, J. C. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin. Cancer Res. 15, 324–329 (2009).
doi: 10.1158/1078-0432.CCR-08-2243
Mattei, J. et al. A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma. Melanoma Res. 30, 574–579 (2020).
doi: 10.1097/CMR.0000000000000694
Hasanov, M. et al. A phase II study of glembatumumab vedotin for metastatic uveal melanoma. Cancers https://doi.org/10.3390/cancers12082270 (2020).
doi: 10.3390/cancers12082270
Patel, S. P. et al. A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Res. 21, 357–363 (2011).
doi: 10.1097/CMR.0b013e3283471073
Shoushtari, A. N. et al. A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma. Melanoma Res. 26, 272–277 (2016).
doi: 10.1097/CMR.0000000000000234
Shoushtari, A. N. et al. A phase Ib study of sotrastaurin, a PKC inhibitor, and alpelisib, a PI3Kα inhibitor, in patients with metastatic uveal melanoma. Cancers https://doi.org/10.3390/cancers13215504 (2021).
doi: 10.3390/cancers13215504
Kraehenbuehl, L. et al. Pilot trial of arginine deprivation plus nivolumab and ipilimumab in patients with metastatic uveal melanoma. Cancers https://doi.org/10.3390/cancers14112638 (2022).
doi: 10.3390/cancers14112638
Ambrosini, G. et al. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. Clin. Cancer Res. 18, 3552–3561 (2012).
doi: 10.1158/1078-0432.CCR-11-3086
Khalili, J. S. et al. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin. Cancer Res. 18, 4345–4355 (2012).
doi: 10.1158/1078-0432.CCR-11-3227
Zimmer, L. et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLoS ONE 10, e0118564 (2015).
doi: 10.1371/journal.pone.0118564
Joshua, A. M. et al. A phase 2 study of tremelimumab in patients with advanced uveal melanoma. Melanoma Res. 25, 342–347 (2015).
doi: 10.1097/CMR.0000000000000175
Algazi, A. P. et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 122, 3344–3353 (2016).
doi: 10.1002/cncr.30258
Karydis, I. et al. Clinical activity and safety of pembrolizumab in ipilimumab pre-treated patients with uveal melanoma. Oncoimmunology 5, e1143997 (2016).
doi: 10.1080/2162402X.2016.1143997
Rossi, E. et al. Pembrolizumab as first-line treatment for metastatic uveal melanoma. Cancer Immunol. Immunother. 68, 1179–1185 (2019).
doi: 10.1007/s00262-019-02352-6
Ny, L. et al. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. Nat. Commun. 12, 5155 (2021).
doi: 10.1038/s41467-021-25332-w
Piulats, J. M. et al. Nivolumab plus ipilimumab for treatment-naive metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J. Clin. Oncol. 39, 586–598 (2021).
doi: 10.1200/JCO.20.00550
Pelster, M. S. et al. Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. J. Clin. Oncol. 39, 599–607 (2021).
doi: 10.1200/JCO.20.00605
Najjar, Y. G. et al. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J. Immunother. Cancer 8, e000331 (2020).
doi: 10.1136/jitc-2019-000331
Heppt, M. V. et al. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. J. Immunother. Cancer 7, 299 (2019).
doi: 10.1186/s40425-019-0800-0
Javed, A. et al. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy 9, 1323–1330 (2017).
doi: 10.2217/imt-2017-0066
Li, X. et al. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat. Rev. Cancer 21, 541–557 (2021).
doi: 10.1038/s41568-021-00383-9
Middleton, M. R. et al. Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clin. Cancer Res. 26, 5869–5878 (2020).
doi: 10.1158/1078-0432.CCR-20-1247
Carvajal, R. D. et al. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nat. Med. https://doi.org/10.1038/s41591-022-02015-7 (2022).
doi: 10.1038/s41591-022-02015-7
Milhem, M. M. et al. Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy [abstract]. J. Clin. Oncol. 37 (Suppl. 15), 9534 (2019).
doi: 10.1200/JCO.2019.37.15_suppl.9534
Wu, X., Li, J., Zhu, M., Fletcher, J. A. & Hodi, F. S. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways. Mol. Cancer Ther. 11, 1905–1914 (2012).
doi: 10.1158/1535-7163.MCT-12-0121
Chen, X. et al. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene 33, 4724–4734 (2014).
doi: 10.1038/onc.2013.418
Piperno-Neumann, S. et al. Genomic profiling of metastatic uveal melanoma and clinical results of a phase I study of the protein kinase C inhibitor AEB071. Mol. Cancer Ther. 19, 1031 (2020).
doi: 10.1158/1535-7163.MCT-19-0098
Kapiteijn, E. et al. A phase I trial of LXS196, a novel PKC inhibitor for metastatic uveal melanoma [abstract]. Cancer Res. 79 (Suppl. 13), CT068 (2019).
doi: 10.1158/1538-7445.AM2019-CT068
Piperno-Neumann, S. et al. A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma. Br. J. Cancer (in the press).
Wagle, M.-C., Ravindran, N., Pankajakshan, D., Lackner, M. & Mounir, Z. Preclinical evaluation of a PKC and MET inhibitor combination in metastatic uveal melanoma [abstract]. Cancer Res. 81 (Suppl. 13), 1343 (2021).
doi: 10.1158/1538-7445.AM2021-1343
IDEAYA Biosciences. IDEAYA reports positive interim phase 2 clinical results for darovasertib and crizotinib synthetic lethal combination in metastatic uveal melanoma. IDEAYA Biosciences https://media.ideayabio.com/2022-09-11-IDEAYA-Reports-Positive-Interim-Phase-2-Clinical-Results-for-Darovasertib-and-Crizotinib-Synthetic-Lethal-Combination-in-Metastatic-Uveal-Melanoma (2022).
Yu, F. X. et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 25, 822–830 (2014).
doi: 10.1016/j.ccr.2014.04.017
Feng, X. et al. A platform of synthetic lethal gene interaction networks reveals that the GNAQ uveal melanoma oncogene controls the Hippo pathway through FAK. Cancer Cell 35, 457–472.e5 (2019).
doi: 10.1016/j.ccell.2019.01.009
Paradis, J. S. et al. Synthetic lethal screens reveal cotargeting FAK and MEK as a multimodal precision therapy for GNAQ-driven uveal melanoma. Clin. Cancer Res. 27, 3190–3200 (2021).
doi: 10.1158/1078-0432.CCR-20-3363
Onken, M. D. et al. Targeting primary and metastatic uveal melanoma with a G protein inhibitor. J. Biol. Chem. 296, 100403 (2021).
doi: 10.1016/j.jbc.2021.100403
Lapadula, D. et al. Effects of oncogenic Gα
doi: 10.1158/1541-7786.MCR-18-0574
Ma, J., Weng, L., Bastian, B. C. & Chen, X. Functional characterization of uveal melanoma oncogenes. Oncogene 40, 806–820 (2021).
doi: 10.1038/s41388-020-01569-5
Hitchman, T. D. et al. Combined inhibition of Gα
doi: 10.1158/1078-0432.CCR-20-2860
Johnson, Z. et al. Preclinical development of a novel, highly selective PI3Kδ inhibitor, IOA-244, for the treatment of solid malignancies [abstract 93P]. Ann. Oncol. 30 (Suppl. 7), vii27 (2019).
doi: 10.1093/annonc/mdz413.097
Faiao-Flores, F. et al. HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma. Clin. Cancer Res. 25, 5686–5701 (2019).
doi: 10.1158/1078-0432.CCR-18-3382
Rago, F. et al. The discovery of SWI/SNF chromatin remodeling activity as a novel and targetable dependency in uveal melanoma. Mol. Cancer Ther. 19, 2186–2195 (2020).
doi: 10.1158/1535-7163.MCT-19-1013
Bigot, J. et al. Splicing patterns in SF3B1-mutated uveal melanoma generate shared immunogenic tumor-specific neoepitopes. Cancer Discov. 11, 1938–1951 (2021).
doi: 10.1158/2159-8290.CD-20-0555
Grimes, J. et al. Clinical characteristics of SF3B1 mutant (mut) uveal melanoma (UM) and response to immune checkpoint inhibition (ICI) [abstract]. J. Clin. Oncol. 39 (Suppl. 15), 9535 (2021).
doi: 10.1200/JCO.2021.39.15_suppl.9535
Fong, J. Y. et al. Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation. Cancer Cell 36, 194–209.e9 (2019).
doi: 10.1016/j.ccell.2019.07.003
Ito, K. et al. PRMT5 inhibition regulates alternative splicing and DNA damage repair pathways in SF3B1 R625G expressing uveal melanoma cells [abstract]. Cancer Res. 81(Suppl. 13), 1137 (2021).
doi: 10.1158/1538-7445.AM2021-1137
Chandran, S. S. et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 18, 792–802 (2017).
doi: 10.1016/S1470-2045(17)30251-6
Fang, D. D. et al. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment. J. Immunother. Cancer 7, 327 (2019).
doi: 10.1186/s40425-019-0750-6
Tolcher, A. W. et al. Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs [abstract]. J. Clin. Oncol. 39 (Suppl. 15), 2506 (2021).
doi: 10.1200/JCO.2021.39.15_suppl.2506
Immunocore. Immunocore presents promising initial phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress. Immunocore https://ir.immunocore.com/news-releases/news-release-details/immunocore-presents-promising-initial-phase-1-data-first-shelf (2022).